Gabe Ortiz, MD, PhD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
AddressLocation Required
Varies CA 00000
Phone628-206-2355
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Yale Univeristy, New Haven, CTMS, BS1996Molecular Biophysics and Biochemistry
    Tri-Institutional MD, PhD Program, New York, NYMD, PhD2004Medicine and Human Immunology
    UCSF, San Francisco, CAResidency2007Internal Medicine
    UCSF, San Francisco, CAChief Residency2008Internal Medicine
    UCSF, San Francisco, CAFellowship2012Infectious Diseases
    University of California, San Francisco, CA2018Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse Overview
    Gabriel Ortiz, MD, PhD, is an Assistant Clinical Professor at UCSF and a hospitalist at Zuckerberg San Francisco General. As the Medical Director of the Medical-Surgical Care Areas, he is focused on quality improvement work to enhance the care delivered to the vulnerable communities served by ZSFG. He is deeply engaged in applying Toyota's LEAN production and LEAN daily management systems as tools for achieving healthcare systems transformation (see links below for more information). Dr. Ortiz is also engaged in the implementation of Epic, the new enterprise EHR planned for ZSFG.

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Clearing the air: inpatient providers' knowledge, perspectives, and experience with electronic cigarettes. J Hosp Med. 2014 Dec; 9(12):805-7. Haber LA, Ortiz GM. PMID: 25352497.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    2. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther. 2014; 11:27. Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM. PMID: 25180041.
      View in: PubMed   Mentions: 2     Fields:    
    3. Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection. PLoS One. 2013; 8(12):e84091. Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM. PMID: 24391889.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    4. Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels. Mol Cell Proteomics. 2012 Sep; 11(9):605-18. Brown JN, Ortiz GM, Angel TE, Jacobs JM, Gritsenko M, Chan EY, Purdy DE, Murnane RD, Larsen K, Palermo RE, Shukla AK, Clauss TR, Katze MG, McCune JM, Smith RD. PMID: 22580588.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    5. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS Res Hum Retroviruses. 2006 Jan; 22(1):52-6. Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, E Sheehy M, Ortiz GM, S Ogg G, Barbour JD, Lenz J, Steinfeld AD, Nixon DF. PMID: 16438646.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    6. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. . 2004 Jul 01; 36(3):791-9. Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. PMID: 15213562.
      View in: PubMed   Mentions:
    7. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. . 2003 Dec 15; 34(5):475-81. Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA. PMID: 14657757.
      View in: PubMed   Mentions:
    8. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol. 2003 Jun; 77(12):6743-52. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. PMID: 12767994.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    9. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS. 2003 Jan 03; 17(1):43-51. García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM. PMID: 12478068.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    10. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS. 2002 Nov 22; 16(17):2342-4. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. PMID: 12441810.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    11. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol. 2002 Jan; 76(1):411-5. Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz MM, Nixon DF. PMID: 11739706.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    12. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A. 2001 Nov 06; 98(23):13288-93. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. PMID: 11687611.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCellsCTClinical Trials
    13. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001 Jun 15; 15(9):F29-40. García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM. PMID: 11416735.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    14. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS. 2000 Oct 20; 14(15):2313-22. Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF. PMID: 11089619.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    15. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000 Sep; 182(3):766-75. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. PMID: 10950770.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    16. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis. 2000 Apr; 181(4):1249-63. Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP. PMID: 10762561.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    17. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999 Sep; 104(6):R13-8. Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M. PMID: 10491418.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    18. “Acinetobacter in military personnel.” Case vignette as part of www.antimicrobe.org. Gabriel M. Ortiz and David Graham. . View Publication.
    Gabe's Networks
    Concepts (88)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (7)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.0.0-839-g49dc76ac on PROFILES-PWEB02.

    Copyright © The Regents of the University of California